In September 2017, MylotargTM was re-approved by the FDA to be used in combination with daunorubicin and cytarabine for the treatment of newly diagnosed CD33+ AML patients and for r/r CD33+ adult and pediatric patients over the age of two. Here, CD33 is linked to acute myeloid leukemia.